Pyxis Oncology
PYXS
54 hedge funds and large institutions have $15.4M invested in Pyxis Oncology in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
13% more funds holding
Funds holding: 48 → 54 (+6)
7.3% less ownership
Funds ownership: 25.11% → 17.81% (-7.3%)
37% less capital invested
Capital invested by funds: $24.6M → $15.4M (-$9.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
+$757K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$360K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$316K |
| 4 |
YF
Yu Fan
|
+$161K |
| 5 |
Two Sigma Advisers
New York
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.58M |
| 2 |
Goldman Sachs
New York
|
-$118K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$116K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$88.5K |
| 5 |
Renaissance Technologies
New York
|
-$85.7K |
PYXS Hedge Fund Activity: Q3 2023 in Review
54 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2023, worth a combined $15.4M — down 37% from $24.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PYXS positions and 7 closed out — a net gain of 7 holders — while 15 added to existing stakes and 13 trimmed.
The largest buyer was Decheng Capital Management III (Cayman), opening a new position worth an estimated $757K. The largest seller was Tang Capital Management, exiting entirely with an estimated $4.58M sold.
- 54 institutional investors held Pyxis Oncology (PYXS) as of Q3 2023, up from 48 in Q2 2023.
- Funds reported $15.4M of Pyxis Oncology stock for Q3 2023, down 37% quarter-over-quarter.
- 14 funds opened new Pyxis Oncology positions in Q3 2023 and 7 closed out, a net change of +7 holders.
- The largest Pyxis Oncology buyer in Q3 2023 was Decheng Capital Management III (Cayman), an estimated $757K added.
- The largest Pyxis Oncology seller in Q3 2023 was Tang Capital Management, an estimated $4.58M sold.
Based on aggregated 13F filings for Q3 2023.